News Agency
Men's Weekly

Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

  • Written by PR Newswire

MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1 multi-center study...

Read more: Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating...

How Headless CMS Enhances Responsive Design and Layout Flexibility

Image by freepik As digital technology continues to evolve at a breakneck pace, users expect much more from content than ever before, and responsive design is crucial to ensure content not only looks but operates across all screens. No longer are... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion